Game-changing cholesterol pill wins FDA approval after cutting LDL nearly 60%

Millions of Americans with high cholesterol now have a new treatment option, as the FDA has approved the first once-daily oral PCSK9 inhibitor. Merck, the New Jersey-based manufacturer of Lipfendra (enlicitide), announced the approval on Thursday. Lipfendra blocks the action of PCSK9, a naturally occurring protein that affects how the liver removes LDL ("bad") cholesterol from the bloodstream. DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN 'JUMPSTART' BETTER HEALTH "PCSK-9 is a pr